The 7 major vernal keratoconjunctivitis markets reached a value of US$ 256.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 348.5 Million by 2034, exhibiting a growth rate (CAGR) of 2.82% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2023 |
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 256.6 Million |
Market Forecast in 2034
|
US$ 348.5 Million |
Market Growth Rate 2024-2034
|
2.82% |
The vernal keratoconjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Vernal Keratoconjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Vernal keratoconjunctivitis (VKC) refers to a rare, chronic allergic disorder primarily affecting the eyes. It typically emerges in children and young adults, particularly in regions with warmer climates. The condition is characterized by inflammation of both the conjunctiva and the cornea. Symptoms of VKC can be distressing, encompassing intense itching, redness, watery discharge, and sensitivity to light. Individuals suffering from the illness might also experience a foreign body sensation in the eye and discomfort. In severe cases, VKC can lead to visual impairment due to complications, such as corneal ulcers or scarring. The diagnosis of this disorder involves a comprehensive eye examination by an ophthalmologist. Clinical features, patient history, and allergic triggers are considered, along with specialized tests like conjunctival scraping and allergen-specific testing. The presence of typical signs such as large papillae (raised bumps) on the conjunctiva under the upper eyelid is often diagnostic.
The increasing cases of exposure to allergens, including pollen, dust mites, animal dander, etc., that can lead to an exaggerated immune response are primarily driving the vernal keratoconjunctivitis market. In addition to this, the inflating utilization of effective pharmaceutical interventions, such as antihistamines, mast cell stabilizers, and corticosteroids to manage symptoms and avert exacerbations is also creating a positive outlook for the market. Moreover, the widespread adoption of cold compresses and lubricating eye drops, as they aid in alleviating discomfort and maintaining ocular moisture in individuals suffering from the illness, is further bolstering the market growth. Apart from this, the rising usage of immunomodulatory agents, which help to regulate the exaggerated immune response underlying the condition, thereby improving the quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of advanced therapies like subconjunctival steroid injections to treat severe cases of VKC is also augmenting the market growth. These procedures provide direct delivery of the medication to the affected area and target the inflammation at its source. Furthermore, the escalating application of tele-ophthalmology consultations for remote diagnosis and treatment plans, since they act as a facilitative element in reaching out to a broader patient population, making healthcare more accessible, is expected to drive the vernal keratoconjunctivitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the vernal keratoconjunctivitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vernal keratoconjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vernal keratoconjunctivitis market in any manner.
Verkazia is a prescription-only oil-in-water cationic emulsion that enhances cyclosporine absorption and effectively manages vernal keratoconjunctivitis. This treatment inhibits T-cell activation, lowering immune cells and mediators that cause chronic and possibly severe allergic inflammation of the ocular surface in people with vernal keratoconjunctivitis.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current vernal keratoconjunctivitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Verkazia (Ciclosporin ophthalmic) | Santen SAS |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Vernal Keratoconjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies